DDInter120 DDInter927
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Arsenic trioxide {u} (Compound) binds {v} (Gene) JUN
Arsenic trioxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Arsenic trioxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Perphenazine
Arsenic trioxide {u} may lead to a major life threatening interaction when taken with {v} Histrelin
Arsenic trioxide (Compound) binds JUN (Gene)
Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Arsenic trioxide may lead to a major life threatening interaction when taken with Perphenazine
Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin